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Introduction
Cardiovascular disease (CVD) is the leading cause of death in both developed and developing countries (1) . A number of prospective human studies have demonstrated the cardioprotective effect of fish. The Physicians' Health Study, which followed 20,551 male physicians for up to 11 years, reported a 52% reduction of sudden cardiac death in males who consumed fish once a week compared to those who ate fish less than once a month (2) . The Nurses' Health Study, which monitored 84,688 women for 16 years, showed an inverse relationship between fish consumption and the incidence of coronary heart disease (3) . In another study that followed 4,738 participants for 12 years, the consumption of tuna or other broiled or baked fish more than five times a week decreased risk of congestive heart failure by 32% compared to a consumption of less than once per month (4) . Inverse relationships between fish consumption and the incidence of stroke have been also reported (5, 6) . The inverse relationships between fish intake and CVD risk observed in the aforementioned studies were independent of cardiovascular risk factors including lifestyle and dietary factors.
The cardioprotective effect of fish is attributed to its content of very long chain omega-3 fatty acids: eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). However, it is unclear whether EPA and DHA have similar biological activity in vivo and similar effects on CVD risk (7) . Indeed, authoritative bodies, including the Food and Agriculture Organization, the World Health Organization, as well as other recognised authoritative scientific bodies, such as the National Heart Foundation of Australia, the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology and the European Atherosclerosis Society, the American Heart Association, and the Dietitians of Canada (8) , recommend a combination of intake of EPA and DHA for primary and secondary prevention of CVD without differentiation in their therapeutic use. However, to date, health claims established for EPA and DHA are approved by the European Food Safety Authority (EFSA) and recently by Health Canada but not by the United State Food and Drug Administration (US FDA). Over 200 clinical trials have examined the effect of EPA and DHA supplements on traditional and nontraditional risk factors of CVD. However, an updated analysis of the evidence is lacking. Such evidence is important for clinical applications, as well as for health claim substantiation related to EPA and DHA. The main objective of the present study was to systematically carry out a meta-analysis of clinical trials in adults to re-evaluate and update the biological effects of EPA and DHA compared to placebo on risk factors associated with CVD, including lipid profile, blood pressure, inflammatory markers, coagulation factors and flow-mediated dilation.
Materials and methods

Literature search
Studies on humans were identified by searching two databases (from the beginning of each database to February 2013), Pubmed and Cochrane Library using the terms "fatty acids", "omega-3", "docosahexaenoic acid", "eicosapentaenoic acid", "fatty acids unsaturated" and "fish oil". The search was limited to studies in humans. In addition, we hand-searched bibliographies of review articles.
Criteria for considering trials
A research assistant screened titles and abstracts of articles examining the effect of omega-3 supplements on risk factors for CVD in adults. Then, potential articles were selected if: (i) they were published as full-length articles in English; (ii) they were reported as a prospective, randomised and controlled trial; (iii) they provided oral purified supplementation of fish oil or EPA and DHA; (iv) they included a placebo or control group; (v) the intervention duration was at least 4 weeks; and (vi) they evaluated any outcome of interest for this analysis. During further evaluation, studies were excluded mainly for reasons such as if: (i) data were incomplete (e.g. a figure lacked sufficient data to calculate mean and standard deviations (SD); (ii) data were reported in another publication; and (iii) the articles did not present results as the mean (SD), standard error (SE), confidence interval (CI) or P-value.
Quality assessment of trials
Randomised controlled studies were assessed for methodological quality with the Jadad score (9) , which focuses on randomisation and randomisation procedures, doubleblinding procedures and the flow of participants. A Jadad score of ≥3 (out of a maximum of 5) was used to indicate that a study is of reasonable quality to be included in this meta-analysis. Quality assessment was carried out independently by a research assistant and the main investigator (SA).
Data extraction
A standardised form was used for data extraction by a research assistant. A reviewer (LA) checked the extracted data for accuracy. Then, data extraction was rechecked independently by two other investigators (SA and RT). Any discrepancy was resolved via review of the original articles. From each study, we extracted information on the first primary author's surname, publication year, study design, sample size, dose and type of intervention and control, carrier used to provide intervention, and intervention duration. In addition, information on participants including age, sex, body mass index and health status was also extracted. From each study, data on mean and SD for all outcomes of interest including lipid profile [total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG)], systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate, C-reactive protein (CRP), tumour necrosis factor (TNF)-a, fibrinogen, platelet count, soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1) and flow-mediated dilation (FMD) were extracted.
Quantitative data synthesis and analysis
The meta-analysis was carried out using COMPREHENSIVE META ANALYSIS, version 2.2.064 (https://www.meta-ana lysis.com). P < 0.05 was considered statistically significant. The difference in means was used to summarise outcomes. For each study, the mean difference in the outcome measures was calculated as the value of the outcome measure at the end of the intervention period minus the value of the outcome measure at the end of the control period. The SD of the mean difference was estimated on the basis of reported SD or SE for intervention and control groups, or based on reported tor P-values for differences in means, if available. For some studies, the P-value cut-off was used if it was only reported that a P-value was below a threshold (e.g. 0.05 if P < 0.05 was reported). For other studies that did not report t-or P-values, the SDs of the mean difference were estimated assuming a conservative 0.5 correlation coefficient between intervention and control measurements.
Random effects models were used to calculate the pooled mean difference (MD) for each outcome measure. Multiple comparisons within studies were combined using a fixed-effects model, and then the random-effects models were used to obtain an overall estimate of intervention on outcomes of interest. Heterogeneity in study results was tested by using the Cochran Q-statistic (P < 0.1). Heterogeneity was quantified by the I 2 statistic. The I 2 provides an estimate of the percentage of variation in study results that is explained by between-study heterogeneity rather than sampling error. An I 2 > 50% indicates considerable heterogeneity. Subgroup analysis by dose size of EPA and DHA was performed for TG. Finally, publication bias was investigated by visual inspection of funnel plots.
Results
More than 14,000 abstracts were screened. A total of 1,580 abstracts was retrieved, of which 244 (all with a Jadad score of ≥3) were considered for data extraction (Fig. 1) . Finally, 171 studies were used in the meta-analysis. This meta-analysis is reported as PRISMA guidelines (Appendix S1). Table 1 presents the characteristics of the included studies. All the studies were randomised, with either cross-over or parallel design. The duration of the clinical studies ranged from 4 to 240 weeks. Most studies included both male and female participants, with mean age ranging from 21 to 74 years. Studies included participants with a variety of health statuses. Trials evaluated mostly the efficacy of fish oil or omega-3 supplements as a modulator of risk factors associated with CVD. The majority of the included studies used supplements that contained a combination of EPA and DHA in doses ranged from 180 mg day À1 to 15000 mg day À1 To reduce bias, we included only randomised placebo-control clinical trials. In addition, most studies were conducted in a double-blind fashion (Table 1) . This meta-analysis revealed that compared with placebo (Table 2) , supplementation with EPA and DHA produces significant reductions of TG of 0.368 mmol L À1 (95% CI = À0.427 to À0.309), SBP of 2.195 mmHg (95% CI = À3.171 to À1.217), DBP of 1.37 mmHg (95% CI = À2.415 to À0.325), heart rate of 1.37 bpm (95% CI = À2.41 to À0.325) and CRP of 0.343 mg L À1 (95% CI = À0.454 to À0.232). This analysis indicates an increase in both LDL-C (MD = 0.150 mmol L
À1
; 95% CI = 0.058-0.243) and HDL-C (MD = 0.039 mmol L
; 95% CI = 0.024-0.054). However, supplementation with EPA and DHA did not significantly affect TC, TNF-a, fibrinogen, platelet count, sICAM-1, sVCAM-1 and /or FMD. The individual study results for the different outcomes are presented as forest plots in the Supporting information (Figures S1 to S14 in Appendix S2).
Subgroup analysis by dose size (see Supporting information, Table S1 in Appendix S2) showed that supplements containing both EPA and DHA reduced TG at different dose size. However, effect size was larger at doses >3 g day À1 . No evidence of publication bias in this analysis was found, as indicated by the funnel plots for TG (Fig. 2) , DBP ( Fig. 3 ) and heart rate ( Fig. 4) .
Discussion
Overall, this meta-analysis of randomised clinical trials showed significant effects of EPA and DHA supplementation on TG, blood pressure, heart rate and CRP. There were small significant increases in both LDL-C and HDL-C concentrations. No effects were found on other risk factors for CVD. The mean differences reported in the present study for lipids are consistent with previous analyses. For example, in an analysis by Eslik et al.
( (14) . Sodium reduction reduces SBP by 4.65 mmHg (14) . Hence, EPA and DHA supplements may be added to other dietary regimens used to control blood pressure. Even modest reductions in blood pressure are most likely of clinical importance (13) . Regarding the results of heart rate, the pooled mean difference of 26 randomised clinical trials showed a reduction in heart rate of approximately 1.37 bpm. A Records idenƟfied through database searching and manual searching (n = 14,041)
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Studies included in final quantitative synthesis (n = 171) Figure 1 Flow chart of the study selection method. previous meta-analysis (15) reported a similar effect of fish oil on heart rate (À1.6 bpm, 95% CI = À0.6 to À2.5) compared to placebo. This analysis provides additional evidence that EPA and DHA supplements affect cardiac electrophysiology in adults.
Chronic inflammation plays an important role in the pathogenesis of CVD. In particular, elevated levels of CRP are associated with an increased risk of the development of CVD (16) . The effects of EPA and/or DHA supplements on inflammatory markers have been investigated recently in many clinical trials. However, this is one of the first meta-analyses to investigate the antiinflammatory effect of EPA and/or DHA supplements. A previous meta-analysis by Balk et al.
(11) examined the effects of omega-3 fatty acids (including a-linolenic acid) on inflammatory markers using data from only four studies and did not find any significant effect. Another metaanalysis by Xin et al.
(17) pooled data from seven trials on patients with chronic heart failure and showed that fish oil supplements reduced the plasma level of TNF-a but not those of CRP, sVCAM-1 and sICAM-1. The results of this updated analysis of 20 clinical studies showed that EPA and/or DHA supplements reduced the plasma levels of CRP. Hence, the effects of EPA and/or DHA supplements on plasma concentrations of inflammatory markers are still inconclusive. Nevertheless, the reductions in CRP (16) . The EFSA has approved Article 13 Health Claims indicating that DHA can maintain normal blood TG levels and that EPA and DHA together can maintain normal heart function and blood pressure (18) . Our data add support to the EFSA approved health claim for EPA and DHA. In addition, our findings are important for other regulatory bodies, such as Health Canada and US FDA, which are considering approving similar claims issued by the EFSA. Recently (May 2016), Health Canada has approved one health claim related to the TG-lowering effect of EPA and DHA. The US FDA has one qualified health claim, based on supportive but not conclusive research, related to omega-3 and cardiovascular risk. A limitation of the present study is that it included only articles in English. However, the main strength of the analysis is that it included only randomised placebo-control clinical trials. Randomisation reduces selection bias. The majority of trials (95%) were conducted in a doubleblind fashion, which reduces performance bias. Therefore, Figure 3 Funnel plots of standard error by differences in means for diastolic blood pressure. evidence generated by our analysis most likely meets the standard of "significant scientific agreement" by US FDA, as well as the criteria set by Health Canada.
The expected intake of EPA and DHA that may produce many cardiovascular related physiological effects, such as a reduction in serum TG levels, blood pressure, heart rate and CRP, is still not known. However, allowing health claims regarding the cardioprotective effects of EPA and DHA could help increase the intake of these fatty acids. The recommended intake of EPA and DHA is 250-500 mg day À1 for the general population as stated by different authorities and agencies (8, 19) . Overall, the results of this updated and comprehensive meta-analysis confirm the lipid-lowering, hypotensive, anti-arrhythmic and anti-inflammatory actions of EPA and DHA supplements. Supplements of EPA and DHA have the potential of offering a cost-effective option to manage hypertriglyceridaemia and improve several markers and/or risk factors associated with CVD. Nevertheless, future studies should look at the effective dose of EPA and DHA that is expected to produce multiple favourable effects on the cardiovascular system.
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